Mihael Musta

Dr. Mihael Musta


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DNDorin Novacescu
Dorin Novacescu
HAHassan abolenein
Hassan abolenein
SLSilviu Constantin Latcu
Silviu Constantin Latcu
Flavia BadercaFlavia Baderca
Flavia Baderca
CSCosmin-Ciprian Secasan
Cosmin-Ciprian Secasan
ACAlin Adrian Cumpanas
Alin Adrian Cumpanas
Background/Objectives: Renal transplantation (RT) remains the gold standard for end-stage renal disease, offering superior outcomes versus dialysis. Despite advances, ureteric complications (leaks/strictures) persist, primarily from ischemic injury, posing substantial graft risks. We review etiology, incidence, and management strategies for post-RT ureteric complications, focusing on surgical reconstruction techniques. Methods: Literature assessment examined ischemic-related ureteric complications. Primary outcomes: incidence, success, complication rates, operative times, and long-term patency. Secondary outcomes: graft/patient survival and reoperation rates. Techniques evaluated included extravesical Lich–Gregoir (L-G) and transvesical Leadbetter–Politano (L-P) ureteroneocystostomy (UNC), Boari flap with psoas hitch, pyelo/ureteroureterostomy, pyelovesicostomy, and ureteroenterostomy. Surgical indications, procedural details, advantages, disadvantages, and quantitative outcomes were systematically analyzed. Results: Ureteric complication incidence ranged from 1 to 15%, with ischemic injury as the primary cause. L-G UNC demonstrated lower complication rates than L-P (6.15% vs. 8.33%) with reduced operative times. Pyelo/ureteroureterostomy achieved excellent salvage outcomes (>90% success, 3.9% reintervention rate). Boari flap provides a suitable option for extensive ureteric defects, consistently preserving graft function without stricture recurrences. Pyelovesicostomy showed 80% long-term success in complex cases. Ureteroenterostomy achieved comparable 5-year graft survival (63%) to standard drainage, despite higher infection rates (65%). Pyelovesicostomy and ureteroenterostomy remain important solutions for specific challenging scenarios. Conclusions: Urinary reconstruction technique selection should be individualized based on anatomical considerations, pathology, and surgical expertise. Comprehensive understanding of reconstruction techniques enables effective management of ureteric complications, preserving graft function and improving outcomes.

5 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
CCCristi Condoiu
Cristi Condoiu
MMMihael Musta
Mihael Musta
ACAlin Adrian Cumpanas
Alin Adrian Cumpanas
RBRazvan Bardan
Razvan Bardan
VDVlad Dema
Vlad Dema
DNDorin Novacescu
Dorin Novacescu
Background: Bladder cancer (BC) is a heterogeneous malignancy, and predicting response to immune checkpoint inhibitors (ICIs) remains a challenge. Herein, we investigate a high-risk bladder tumor, which developed during anti-BRAF/MEK therapy for a concurrent advanced BRAF-V600E-positive malignant melanoma (MM) and subsequently underwent complete spontaneous necrosis following Nivolumab immunotherapy, only to recur thereafter while still under the same treatment. This unique scenario provided an opportunity to investigate the roles of BRAF gene mutations in BC pathogenesis, respectively, of PD-L1 expression in immunotherapy response prediction. Methods: We retrospectively analyzed BC specimens obtained via transurethral resection at two critical time-points: prior to the complete spontaneous necrosis under Nivolumab (prenecrosis) and after tumor recurrence postnecrosis (postnecrosis). The BRAF gene mutation status was evaluated using quantitative polymerase chain reaction (qPCR). PD-L1 expression was assessed by immunohistochemistry (IHC), quantified using the combined positive score (CPS), and a cutoff of ≥10 for positivity. Results: Neither pre- nor postnecrosis BC samples harbored BRAF gene mutations. Prenecrosis PD-L1 expression (CPS = 5) indicated a minimal likelihood of response to immunotherapy. However, complete spontaneous necrosis occurred under Nivolumab, followed by recurrence with further reduced PD-L1 expression (CPS = 1). Conclusions: The complete BC regression challenges the conventional role of PD-L1 as a sole predictive biomarker for immunotherapy. This study also highlights the potential role of BRAF/MEK inhibitors in BC oncogenesis and underscores the need for alternative biomarkers, such as tumor mutation burden (TMB) and circulating tumor DNA (ctDNA), to guide treatment selection in BC better.

7 November 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DNDorin Novacescu
Dorin Novacescu
MMMihael Musta
Mihael Musta
RCRadu Caprariu
Radu Caprariu
Cristina-Stefania DumitruCristina-Stefania Dumitru
Cristina-Stefania Dumitru
ABAlina Cristina Barb
Alina Cristina Barb
Flavia BadercaFlavia Baderca
Flavia Baderca
Immune checkpoint inhibitors (ICIs) are established across the treatment continuum of urothelial carcinoma of the bladder, yet most patients derive no durable benefit. This narrative review appraises candidate predictors of ICI benefit in bladder urothelial carcinoma, distinguishing prognostic from predictive biomarkers, applying the same three evidentiary standards to every biomarker, classifying the supporting studies by design and separating evidence from regulatory status. Programmed death-ligand 1 (PD-L1) immunohistochemistry meets the enrichment standard in three co-primary PD-L1-positive populations, in trials also positive overall, but not the predictive standard: its four registrational assays are not interchangeable; randomized comparisons show inconsistent subgroup effects, failed prespecified tests in IMvigor211 and DANUBE and no significant treatment-by-PD-L1 interaction; and the benefit of first-line enfortumab vedotin plus pembrolizumab is independent of combined positive score. Its remaining role is confined to label restrictions, chiefly European. Tumor mutational burden, molecular subtypes, expression signatures, DNA damage response and FGFR3 alterations remain investigational. Tumor-informed circulating tumor DNA (ctDNA) answers a different question: whether residual disease persists after cystectomy. After an exploratory signal in IMvigor010, the prospective enrichment trial IMvigor011 showed that ctDNA-positive patients derive disease-free and overall survival benefit from adjuvant atezolizumab; persistently ctDNA-negative patients were observed without randomization, so their 88% two-year disease-free survival does not exclude a benefit of treatment. This underpins US companion-diagnostic approval and a Category 1 guideline recommendation, not yet European authorization. Post-cystectomy ctDNA thus meets the same enrichment standard as PD-L1 and, like PD-L1, neither the predictive nor the strategy standard; what sets it apart is that the marker was necessary for the result, adjuvant atezolizumab having failed unselected, and that it directs whether to treat rather than which regimen; its role after perioperative immunotherapy is unresolved.